Literature DB >> 8035038

Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska 1986-1990.

A J Parkinson1, M Davidson, M A Fitzgerald, L R Bulkow, D J Parks.   

Abstract

From January 1986 through December 1990, 672 cases of invasive pneumococcal disease were identified. From these, 574 pneumococcal isolates were recovered from normally sterile sites (blood, cerebrospinal and pleural fluid); 92% were serotypes represented in the 23-valent pneumococcal polysaccharide vaccine. The most common serotypes from children < 2 years old were 4, 6B, 9V, 14, 18C, 19F, and 23F, recovered from 83% of Alaska Native and 75.1% of nonnative children with invasive disease. Moderate penicillin resistance (MIC, 0.1-1.0 micrograms/mL) was found in 3.8% of isolates. All were sensitive to chloramphenicol, vancomycin, rifampin, ceftriaxone, cefotaxime, cephalothin, and cefaclor. However, in the Yukon-Kuskokwim Delta region, 16.9% of isolates were moderately resistant to penicillin, and 10.8% were resistant to erythromycin and 6.2% to trimethoprim-sulfamethoxazole; the number resistant to two or more antibiotics increased significantly during surveillance. All multiply resistant isolates were serotype 6B, and all were from Alaska Native patients < 2 years old.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035038     DOI: 10.1093/infdis/170.2.461

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Genetic relatedness within and between serotypes of Streptococcus pneumoniae from the United Kingdom: analysis of multilocus enzyme electrophoresis, pulsed-field gel electrophoresis, and antimicrobial resistance patterns.

Authors:  L M Hall; R A Whiley; B Duke; R C George; A Efstratiou
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

2.  Molecular analysis by pulsed-field gel electrophoresis and antibiogram of Streptococcus pneumoniae serotype 6B isolates from selected areas within the United States.

Authors:  K M Rudolph; A J Parkinson; M C Roberts
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

3.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.

Authors:  J B Rubins; M Alter; J Loch; E N Janoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  Pneumococcal meningitis in the North East Thames Region UK: epidemiology and molecular analysis of isolates.

Authors:  G Urwin; M F Yuan; L M Hall; K Brown; A Efstratiou; R A Feldman
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

6.  Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in central Australia.

Authors:  M Gratten; P Torzillo; F Morey; J Dixon; J Erlich; J Hagger; J Henrichsen
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

7.  Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94.

Authors:  S V Nielsen; J Henrichsen
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

8.  Serotypes and resistance patterns of Streptococcus pneumoniae causing systemic disease in northern Norway.

Authors:  T Magnus; B M Andersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

9.  Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections.

Authors:  R F Jacobs; S L Kaplan; G E Schutze; A S Dajani; R J Leggiadro; C S Rim; S K Puri
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.